Semper Paratus Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to pursue an acquisition opportunity in the transportation, supply chain, and logistics industry. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.semperparatusspac.com
| Date | Price Target | Rating | Analyst |
|---|
Fastest customizable press release news feed in the world
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen Bio"), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc's previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc. The combined company's common s
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW, LGSTU))), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the "Business Combination") with Tevogen Bio Inc, a Delaware corporation ("Tevogen Bio"), at an extraordinary general meeting of Semper Paratus' shareholders that was held on Wednesday, January 31, 2024 (the "Meeting"). Each of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable following the satisfaction or waiver of the remaining c
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW))), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement ("Prospectus Supplement") to its definitive proxy statement/prospectus dated January 10, 2024 (the "Proxy Statement/Prospectus") for the solicitation of proxies in connection with the extraordinary general meeting of Semper Paratus' shareholders scheduled to be held on January 29, 2024, to consider and vote on, among other proposals as more fully set forth in the Proxy Statement/Prospectus, the transactions (collectively, the "Business Combination") contemplated
The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc ("Tevogen Bio") stockholders is an expected $1.2 billion.Tevogen Bio is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Inc ("Tevogen Bio"), an advanced-stage specialty immunotherapy biotech pioneer and Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW))), a publicly-traded special purpose acquisition company, today announced that the Securities and Exchange Commission ("SEC") has declared e
New York, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (NASDAQ:LGST, the "Company"))) announced today that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") confirming that the Company had regained compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires the Company to maintain a Market Value of Listed Securities ("MVLS") of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market (the "MVLS Rule"). As previously disclosed, the Company was notified by the Listing Qualifications Department of Nasdaq that it did not comply with the MVLS Rule. The Company has maintained a MVLS
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (NASDAQ:LGST) ("Semper Paratus"), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission relating to Semper Paratus' previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. The Registration Statement contains a preliminary proxy statement and prospectus in connection with the pr
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
3 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)
8-K/A - Tevogen Bio Holdings Inc. (0001860871) (Filer)
8-A12B - Semper Paratus Acquisition Corp (0001860871) (Filer)
8-K - Semper Paratus Acquisition Corp (0001860871) (Filer)
25-NSE - Semper Paratus Acquisition Corp (0001860871) (Subject)
425 - Semper Paratus Acquisition Corp (0001860871) (Subject)
8-K - Semper Paratus Acquisition Corp (0001860871) (Filer)
425 - Semper Paratus Acquisition Corp (0001860871) (Subject)
424B3 - Semper Paratus Acquisition Corp (0001860871) (Filer)
425 - Semper Paratus Acquisition Corp (0001860871) (Subject)
This live feed shows all institutional transactions in real time.
SC 13D - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13D - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13G/A - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G/A - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G/A - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G - Semper Paratus Acquisition Corp (0001860871) (Subject)
SC 13G/A - Semper Paratus Acquisition Corp (0001860871) (Subject)